When to Check Anti-TPO and Anti-TSH Receptor Antibodies
Check anti-TSH receptor antibodies (TRAb) first-line when thyrotoxicosis is confirmed to establish the diagnosis of Graves' disease, and measure anti-TPO antibodies in subclinical hypothyroidism to predict progression to overt disease.
Anti-TSH Receptor Antibodies (TRAb)
In Hyperthyroidism/Thyrotoxicosis
- Order TRAb immediately when TSH is suppressed and free T4 is elevated to confirm Graves' disease 1
- Modern TRAb assays have sensitivity and specificity approaching 100%, making them the definitive test for Graves' disease 1
- If TRAb is positive, no additional etiologic testing (ultrasound, scintigraphy) is necessary in typical presentations (young female, homogeneous goiter, ophthalmopathy) 1
- In atypical presentations, TRAb should be first-line alongside or instead of imaging 1
In Pregnancy - Critical Timing
Measure TRAb in pregnant women with current or past Graves' disease at specific gestational windows:
- At 20-26 weeks gestation (or first trimester if elevated, then repeat at 20-26 weeks) in hypothyroid pregnant patients with history of Graves' disease treated with radioactive iodine or thyroidectomy 2
- This timing is crucial because elevated TRAb predicts fetal/neonatal thyroid dysfunction with high correlation 2
- At diagnosis if Graves' disease is identified during pregnancy, then repeat at 22-26 weeks if initially elevated 3
- When etiology of hyperthyroidism in pregnancy is uncertain 3
The rationale: TRAb crosses the placenta and can cause fetal hyperthyroidism even in mothers who are hypothyroid after definitive treatment 2, 4.
Anti-TPO Antibodies
In Hypothyroidism
Measure anti-TPO when evaluating subclinical hypothyroidism (elevated TSH with normal free T4) 2
- Anti-TPO positivity predicts progression to overt hypothyroidism at 4.3% per year versus 2.6% per year when negative 2, 5
- This helps guide the decision to treat versus monitor, though the 2012 AACE/ATA guideline notes this is predictive rather than diagnostic, hence Grade B recommendation 2
Check anti-TPO when nodular thyroid disease is suspected to be due to autoimmune thyroiditis 2
In Reproductive Health
Measure anti-TPO in women with recurrent miscarriage, with or without infertility 2
- This is a Grade A recommendation due to favorable risk-benefit potential 2
- Anti-TPO positive women are at increased risk for progression of hypothyroidism and should be screened for TSH abnormalities before pregnancy and during first and second trimesters 6
In Confirmed Thyrotoxicosis with Negative TRAb
If TRAb is negative in a patient with confirmed thyrotoxicosis, measure anti-TPO to assess for autoimmune thyroiditis (Hashimoto's thyroiditis), which almost always shows positive anti-TPO 1
Algorithmic Approach
For Suspected Hyperthyroidism:
- Confirm with suppressed TSH + elevated free T4
- Order TRAb immediately for etiologic diagnosis
- If TRAb positive → Graves' disease confirmed
- If TRAb negative → Check anti-TPO to evaluate for autoimmune thyroiditis
For Subclinical Hypothyroidism:
- Confirm with elevated TSH (repeat in 2 weeks to 3 months) + normal free T4
- Measure anti-TPO to predict progression risk
- If TSH >10 mIU/L: stronger basis for treatment regardless of antibodies
- If TSH 4.5-10 mIU/L: anti-TPO helps guide treat-versus-monitor decision
For Pregnancy:
- History of Graves' disease (treated with RAI/thyroidectomy) → TRAb at 20-26 weeks (or first trimester then 20-26 weeks)
- Active Graves' disease in pregnancy → TRAb at diagnosis, repeat at 22-26 weeks if elevated
- Recurrent miscarriage/infertility → Anti-TPO before or early in pregnancy
Common Pitfalls
- Don't routinely measure anti-TPO in all thyroid nodule patients unless nodular disease is suspected to be due to hypothyroidism 2, 7
- Don't use anti-TPO to diagnose hypothyroidism - it only predicts risk of progression in subclinical disease 2
- Don't delay TRAb measurement in pregnancy - the 20-26 week window is critical for assessing fetal risk 2, 3
- Be aware of assay variability - anti-TPO thresholds range from 4-120 IU/L depending on the method 1
- Don't order TRAb in typical Graves' disease if diagnosis is clinically obvious (young female, goiter, ophthalmopathy), though it can still be useful for treatment decisions 1